Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus lenvatinib neoadjuvant and adjuvant therapy for locally advanced gallbladder cancer
ChiCTR2300069480Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and lenvatinib in gallbladder cancer and cholangiocarcinoma (CCA), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: R0 resection rate. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
camrelizumablenvatinib
03
Conditions
gallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2300069480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069480.